This observational study will evaluate the safety, tolerability and efficacy of RoActemra/Actemra (tocilizumab) in combination with methotrexate in patients with moderate to severe rheumatoid arthritis. Data will be collected for 12 months from patients initiated on treatment with RoActemra/Actemra (8 mg/kg intravenously every 4 weeks) and methotrexate (weekly dose at the discretion of the physician).
Read more: http://www.clinicaltrials.gov/ct2/show/NCT01384461?cond=%22Arthritis%22&lup_s=08/23/2013&lup_d=30
